IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Maurice Winn who wrote (1468)	2/4/1998 8:13:00 PM
From: Gregory Rasp	Read Replies (2) of 1762

Yttrium 90 does look much more promising than Rituxan according to the recent Mayo Clinic trial. As for life extension that would seem like a no-brainer to me also but I can tell you that there are several sites where the addition of radiation improves median survival but is rarely offered to the patient under the thought that 6 months is not worth $6-10K. The real problem for Rituxan is proof that it improves survival. I am not aware of any. Since we first started talking the drug is now being marketed aggressively in Ohio. All of the advertising claims tumor response but no mention of its use in the adjuvant setting. I will get those two abstracts for you. Greg BTW - IMHO Stanford is the preeminent lymphoma center in the US. Dr. Hoppe as a radiation oncologist is hard to beat.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next